{"id":127289,"date":"2021-09-05T21:22:17","date_gmt":"2021-09-06T04:22:17","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/09\/anti-cd7-car-t-therapy-yields-high-response-rate-in-acute-leukemia"},"modified":"2021-09-05T21:22:17","modified_gmt":"2021-09-06T04:22:17","slug":"anti-cd7-car-t-therapy-yields-high-response-rate-in-acute-leukemia","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/09\/anti-cd7-car-t-therapy-yields-high-response-rate-in-acute-leukemia","title":{"rendered":"Anti-CD7 CAR-T Therapy Yields High Response Rate in Acute Leukemia"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/anti-cd7-car-t-therapy-yields-high-response-rate-in-acute-leukemia2.jpg\"><\/a><\/p>\n<p>Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r\/r) T-cell acute lymphoblastic (ALL), a first-in-human clinical trial showed.<\/p>\n<p>After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation (SCT). All patients developed cytokine release syndrome (CRS), which was grade 1\/2 in most instances. Because the therapy involved unmanipulated T cells, a majority of patients developed graft-versus-host disease (GVHD), grade 1\/2 severity in all cases. All of the patients developed severe cytopenias, which were manageable.<\/p>\n<p>The results provided the basis for an ongoing phase II trial of the donor-derived anti-CD7 therapy, reported Jing Pan, MD, of the State Key Laboratory of Experimental Hematology and Beijing Boren Hospital in China, and colleagues in the <a href=\"https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.21.00389\" target=\"_blank\"><em>Journal of Clinical Oncology<\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r\/r) T-cell acute lymphoblastic (ALL), a first-in-human clinical trial showed. After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation (SCT). [\u2026]<\/p>\n","protected":false},"author":621,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-127289","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/127289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/621"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=127289"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/127289\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=127289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=127289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=127289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}